Cell-Free Fetal DNA Testing Market

Cell-Free Fetal DNA Testing Market: Global Industry Analysis and Opportunity Assessment 2016-2026 Overview

Cell-free fetal DNA is an extension of prenatal testing in a safe and non-invasive method. Prenatal tests are used to find any irregularities in a fetus. The two predominant prenatal tests are chorionic villus sampling (CVS) and amniocentesis, both are invasive and could possess harm to the developing fetus, in some cases it can cause miscarriage.

Cell-free fetal DNA is a new alternative of prenatal tests. Fetal DNA is found in mother’s blood stream, cell-free fetal DNA enters into the blood stream through the placenta, placenta is a flattened organ in the uterus where maternal blood and fetal blood. The fetal DNA can be split into very acute fragments, less than 200 base pairs on an average.

Maternal DNA fragments are also present in the blood. Fetal DNA is first noticed after 22-25 days of fertilization and its concentrations increase as the time period of pregnancy increases. Diagnostic tests for pregnancy using fetal DNA is possible in seventh week of pregnancy. Fetal DNA can be rarely distinguished from the maternal DNA through diagnostic practice.

Amniocentesis and chorionic villus sampling prenatal test is possible within 14-20 weeks and 10-13 weeks of pregnancy respectively. Cell-free fetal DNA non-invasive test is used to detect aneuploidy syndromes, fetal Down syndrome and signals a major shift in diagnostic practice and prenatal screening.

Cell-Free Fetal DNA Testing Market: Drivers and Restraints

The primary factor for the growth of global cell-free fetal DNA testing market is growing awareness in the people andrequirement of safe or low risk obstetric procedures for prenatal testing. The technology which is used in cell-free DNA analysis and its application to prenatal screening for aneuploidy is rapidly changing.

The growth of cell-free fetal DNA testing market is primarily attributed to accurate and effective results for aneuploidy screening. Major factor which limits the growth of the global cell-free fetal DNA testing market is high cost of cell-free fetal DNA tests.

Cell-Free Fetal DNA Testing Market: Overview

The cell-free fetal DNA testing enables the parents to get information about general survivable fetal aneuploidies with a high accuracy and without any diagnostic procedure risk. In comparison with other screening method of aneuploidy, cell-free fetal DNA testing offers various advantages such as lower false-positive results of cell-free fetal DNA test as compared to other screening method.

Aneuploidy is an unusual number of chromosome, typically characterized by the absence of one copy of a single chromosome or by the increase in the amount of chromosomes. The presence of an extra copy of chromosome 21 is called trisomy 21, which causes Down syndrome.

Cell-Free Fetal DNA Testing Market: Region-wise Outlook

The global cell-free fetal DNA testing market is expected to register a healthy CAGR for the forecast period. Depending on geographic region, global cell-free fetal DNA testingmarket is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa.

North America held largest share in the global market of cell-free fetal DNA testingfollowed by Europe, Japan and Asia Pacific owing to high occurrence of several diseases and increasing number of aneuploidies, great advancement in field of aneuploidy screeningand developed healthcare infrastructure. The developing nations in Asia Pacific, Middle East and Africa hold huge potential for growth in the global cell-free fetal DNA testingmarket, due to its quick and accurate result without any risk to developing fetus.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Cell-Free Fetal DNA testing Market: Key Players

Some of the key participating global players in cell-free fetal DNA testingglobal market are Sequenom Laboratories, Illumina, Inc., Ariosa Diagnostics, Arup Laboratories, The Fetal Medicine Centre, Apollo Path labs.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Sign-Up

Regional analysis includes

• North America (U.S., Canada)
• Latin America (Mexico, Brazil, Rest of Latin America)
• Western Europe (Germany, Italy, U.K, Spain, France, Rest of Western Europe)
• Eastern Europe (Poland, Russia, Rest of Eastern Europe)
• Asia Pacific (China, India, ASEAN, Australia & New Zealand)
• Japan
• Middle East and Africa (GCC, S. Africa, Rest of MEA)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Cell-Free Fetal DNA Testing Market: Segmentation

Global cell-free fetal DNA testingmarket is classified on the basis of types of cell-free fetal DNA tests and geography

Based on test types, the global cell-free fetal DNA testing market is segmented into the following:

• Detection of Abnormal Chromosome Number
• Gender Testing
• Paternally Inherited Disorders